AbbVie Inc. (NYSE:ABBV) Q2 2024 Earnings Conference Call July 25, 2024 9:00 AM ET
Company Participants
Liz Shea - Senior Vice President, Investor Relations
Rob Michael - Chief Executive Officer
Jeff Stewart - Executive Vice President and CCO
Roopal Thakkar - Executive Vice President, Research and Development and CSO
Scott Reents - Executive Vice President and CFO
Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics
Conference Call Participants
Terence Flynn - Morgan Stanley
Chris Schott - JPMorgan
Carter Gould - Barclays
Vamil Divan - Guggenheim
Chris Shibutani - Goldman Sachs
Mohit Bansal - Wells Fargo
Chris Raymond - Piper Sandler
Gary Nachman - Raymond James
Steve Scala - TD Cowen
Trung Huynh - UBS
Evan Seigerman - BMO Capital Markets
James Shin - Deutsche Bank
Louise Chen - Cantor Fitzgerald
Operator
Good morning and thank you for standing by. Welcome to the AbbVie Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer portion of this call. [Operator Instructions]
I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.
Liz Shea
Good morning and thanks for joining us. Also on the call with me today are Rob Michael, Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; Scott Reents, Executive Vice President, Chief Financial Officer; and Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics.
Before we get started, I’ll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements except as required by law.
On today’s conference call, non-GAAP financial measures will be used to help investors understand AbbVie’s business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we’ll take your questions.
So, with that, I’ll turn the call over to Rob.
Rob Michael
Thank you, Liz. Good morning, everyone, and thank you for joining us. It’s a pleasure to speak with you today as AbbVie’s new CEO. I look forward to building on our track record of success and delivering on AbbVie’s promise to our patients, employees, shareholders and communities.